尤瑞克林治疗急性脑梗死患者的临床效果
|
摘要
目的探讨尤瑞克林治疗急性脑梗死患者中的临床效果。方法选择2017年11月～2018年11月我院收治的急性脑梗死患者80例,按照随机数字表法分为对照组和观察组,各40例。两组均给予常规方法治疗,对照组采用依达拉奉治疗,观察组在对照组基础上采用尤瑞克林治疗,比较两组临床疗效、C-反应蛋白与神经功能缺损程度评分。结果观察组总有效率为95.00%,高于对照组的85.00%,差异有统计学意义(P<0.05)。治疗后,观察组C-反应蛋白与神经功能缺损程度评分均低于对照组[(8.92±0.84)mg/dl vs(12.36±1.25)mg/dl,(4.61±0.92)分vs(9.63±1.64)分],差异有统计学意义(P<0.05)。结论尤瑞克林治疗急性脑梗死患者疗效显著,可促进神经功能恢复,改善预后,具有较高的临床应用价值。
Objective To investigate the clinical effects of Ureklin in patients with acute cerebral infarction. Methods 80 patients with acute cerebral infarction admitted to our hospital from November 2017 to November 2018 were enrolled. The patients were divided into the control group and the observation group according to the random number table method, 40 cases each. The two groups were treated with conventional methods. The control group was treated with edaravone. The observation group was treated with Ureklin on the basis of the control group. The clinical efficacy, C-reactive protein and neurological deficit scores were compared between the two groups. Results The total effective rate of the observation group was 95.00%,which was higher than that of the control group 85.00%,the difference was statistically significant(P<0.05). After treatment, the C-reactive protein and neurological deficit scores in the observation group were lower than those in the control group [(8.92 ±0.84) mg/dl vs(12.36±1.25) mg/dl,(4.61±0.92) scores vs(9.63±1.64) scores, the difference was statistically significant(P<0.05). Conclusion Ureklin is effective in the treatment of patients with acute cerebral infarction, which can promote the recovery of neurological function and improve the prognosis. It has high clinical value.
Objective To investigate the clinical effects of Ureklin in patients with acute cerebral infarction. Methods 80 patients with acute cerebral infarction admitted to our hospital from November 2017 to November 2018 were enrolled. The patients were divided into the control group and the observation group according to the random number table method, 40 cases each. The two groups were treated with conventional methods. The control group was treated with edaravone. The observation group was treated with Ureklin on the basis of the control group. The clinical efficacy, C-reactive protein and neurological deficit scores were compared between the two groups. Results The total effective rate of the observation group was 95.00%,which was higher than that of the control group 85.00%,the difference was statistically significant(P<0.05). After treatment, the C-reactive protein and neurological deficit scores in the observation group were lower than those in the control group [(8.92 ±0.84) mg/dl vs(12.36±1.25) mg/dl,(4.61±0.92) scores vs(9.63±1.64) scores, the difference was statistically significant(P<0.05). Conclusion Ureklin is effective in the treatment of patients with acute cerebral infarction, which can promote the recovery of neurological function and improve the prognosis. It has high clinical value.
引文
[1]杜春艳,赵中.尤瑞克林对急性脑梗死患者临床疗效及脑血管储备功能的影响[J].贵州医药,2017,41(4):371-372.
[2]陆伟恒,罗成宏,廖成钜,等.尤瑞克林联合阿司匹林对急性脑梗死患者血清学指标及临床疗效的影响[J].实用医学杂志,2017,33(21):3615-3618.
[3]何晓晓,刘雨薇,刘承云,等.尤瑞克林对急性脑梗死患者红细胞压积及凝血指标水平的影响:回顾性队列研究[J].卒中与神经疾病,2017,24(1):54-57.
[4]冀玉婷,崔莉红.加用尤瑞克林对急性分水岭脑梗死患者神经功能及生活质量恢复的影响[J].实用药物与临床,2017,20(7):797-800.
[5]王红.尤瑞克林治疗急性脑梗死患者78例临床疗效分析[J].中外医疗,2016(7):121-122.
[6]李兵,胡世颉,闫志强,等.尤瑞克林和依达拉奉联合治疗急性脑梗死患者的临床效果及安全性[J].中国医药,2017,12(6):865-868.
[7]曹军.尤瑞克林联合针刺对急性脑梗死病人S100B、MMP-9、TIMP-1及NIHSS评分的影响[J].中西医结合心脑血管病杂志,2017,15(11):1392-1395.
[2]陆伟恒,罗成宏,廖成钜,等.尤瑞克林联合阿司匹林对急性脑梗死患者血清学指标及临床疗效的影响[J].实用医学杂志,2017,33(21):3615-3618.
[3]何晓晓,刘雨薇,刘承云,等.尤瑞克林对急性脑梗死患者红细胞压积及凝血指标水平的影响:回顾性队列研究[J].卒中与神经疾病,2017,24(1):54-57.
[4]冀玉婷,崔莉红.加用尤瑞克林对急性分水岭脑梗死患者神经功能及生活质量恢复的影响[J].实用药物与临床,2017,20(7):797-800.
[5]王红.尤瑞克林治疗急性脑梗死患者78例临床疗效分析[J].中外医疗,2016(7):121-122.
[6]李兵,胡世颉,闫志强,等.尤瑞克林和依达拉奉联合治疗急性脑梗死患者的临床效果及安全性[J].中国医药,2017,12(6):865-868.
[7]曹军.尤瑞克林联合针刺对急性脑梗死病人S100B、MMP-9、TIMP-1及NIHSS评分的影响[J].中西医结合心脑血管病杂志,2017,15(11):1392-1395.